KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Inventory (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Inventory for 14 consecutive years, with $82.4 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 51.74% to $82.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $82.4 million through Dec 2025, up 51.74% year-over-year, with the annual reading at $82.4 million for FY2025, 51.74% up from the prior year.
  • Inventory for Q4 2025 was $82.4 million at Supernus Pharmaceuticals, up from $79.4 million in the prior quarter.
  • The five-year high for Inventory was $91.5 million in Q4 2022, with the low at $44.0 million in Q2 2025.
  • Average Inventory over 5 years is $73.1 million, with a median of $78.4 million recorded in 2023.
  • The sharpest move saw Inventory soared 105.69% in 2021, then tumbled 35.41% in 2025.
  • Over 5 years, Inventory stood at $86.0 million in 2021, then grew by 6.49% to $91.5 million in 2022, then dropped by 15.44% to $77.4 million in 2023, then decreased by 29.86% to $54.3 million in 2024, then surged by 51.74% to $82.4 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $82.4 million, $79.4 million, and $44.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.